{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:04:55Z","timestamp":1791072295436,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":3630,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:p> <jats:bold>Summary<\/jats:bold>\n          <jats:sc>objective<\/jats:sc>\u2002\u2002With the use of a specific high\u2010performance liquid chromatography (HPLC) method and a bioassay which determines trypanocidal activity concentrations of melarsoprol were assassed in plasma, urine and cerebrospinal fluid (CSF) from 8 patients with late\u2010stage <jats:italic>Trypanosoma gambiense<\/jats:italic> sleeping sickness. The aim was to unravel to what extent the bioassay codetermines biologically active metabolites of melarsoprol.<\/jats:p><jats:p> <jats:sc>methods<\/jats:sc>\u2002\u2002Subjects were given one dose of melarsoprol i.v. per day for 4 days (1.2, 2.4, 3.0\u20133.6, 3.0\u20133.6 mg per kg b.w., respectively). Plasma samples were obtained before the first melarsoprol injection, immediately after and at 1 h, 24 h and 5 days after the 4th injection. Urine was collected before melarsoprol therapy and at 24 h after the 4th injection. CSF samples were taken once before treatment and at 24 h after the 4th injection.<\/jats:p><jats:p> <jats:sc>results<\/jats:sc>\u2002\u2002HPLC analyses showed that plasma concentrations immediately after the 4th injection varied from 2200 to 15 900 nmol\/l; dropping to 0\u20131800 nmol\/l at 1 h; and to undetectable levels at 24 h. In urine small amounts of melarsoprol were recovered. Melarsoprol could not be detected in CSF by HPLC. Immediately after injection, bioassay analyses showed plasma concentrations of the same magnitude as HPLC assays but at 1 h they were 4\u201365\u2010fold higher than the levels assessed by HPLC. Even 24 h and 5 days after the 4th injection there was significant but decreasing activity. Urine levels were 40\u2013260\u2010fold higher than the measured HPLC concentrations, whereas there was low but detectable activity in CSF.<\/jats:p><jats:p> <jats:sc>conclusion<\/jats:sc>\u2002\u2002Results indicate that melarsoprol is rapidly eliminated from plasma. The significant trypanocidal activity determined by bioassay and simultaneuos low or undetectable levels of melarsoprol assayed by HPLC indicate that the compound is transformed into metabolites with parasiticidal activity.<\/jats:p>","DOI":"10.1046\/j.1365-3156.1998.00327.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:30:39Z","timestamp":1047504639000},"page":"913-917","source":"Crossref","is-referenced-by-count":21,"title":["Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with <i>T. gambiense<\/i> sleeping sickness indicates that melarsoprol is metabolized"],"prefix":"10.1111","volume":"3","author":[{"family":"Bronner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Doua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Burri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mi\u00e9zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Boa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(83)90022-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04451.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239130"},{"key":"e_1_2_6_5_2","first-page":"65","article-title":"Alternative application of melarsoprol for treatment of T.b. gambiense sleeping sickness.","volume":"75","author":"Burri C","year":"1995","journal-title":"Annales de la Societ\u00e9 Belge M\u00e9decine Tropicale"},{"key":"e_1_2_6_6_2","first-page":"223","article-title":"An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid.","volume":"43","author":"Burri C","year":"1992","journal-title":"Tropical Medicine and Parasitology"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706X(94)90120-1"},{"key":"e_1_2_6_8_2","first-page":"389","article-title":"\u00c9tude de l'excr\u00e9tion de l'arsenic chez le trypanosome trait\u00e9 au m\u00e9larsorpol (Arsobal?).","volume":"35","author":"Cristau B","year":"1975","journal-title":"Medecine Tropicale (Marseilles)"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1987.37.525"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(96)00418-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(96)90533-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1948.11685383"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(79)90092-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-308X(08)60410-8"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(85)90195-6"},{"key":"e_1_2_6_16_2","unstructured":"WHO Technical report series739."},{"key":"e_1_2_6_17_2","unstructured":"The African Trypanosomiases. (eds. HW Mulligan & WH Potts) George Allen and Unwin London pp. 125\u2013221."}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-3156.1998.00327.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3156.1998.00327.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-3156.1998.00327.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3156.1998.00327.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:32:43Z","timestamp":1694424763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-3156.1998.00327.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1046\/j.1365-3156.1998.00327.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-3156.1998.00327.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]}}}